Skip to content


Cancer Imaging

Open Access

Gadobenate dimeglumine (MultiHance) or gadoterat emeglumine (Dotarem) for brain tumour imaging? An intra-individual comparison

  • M Vaneckova1,
  • M Herman1,
  • MP Smith1,
  • M Mechl1,
  • KR Maravilla1,
  • C Colosimo1,
  • A Bonafé1,
  • S Lui1,
  • MA Kirchin1Email author and
  • G Pirovano1
Cancer Imaging201515(Suppl 1):P15

Published: 2 October 2015


Brain TumourMeaningful DifferenceSafety AssessmentDiagnostic InformationStudy Agent


To intra-individually compare 0.1 and 0.05 mmol/kg gadobenate (MultiHance) with 0.1 mmol/kg gadoterate (Dotarem) for contrast-enhanced MRI of brain tumours.

Method and materials

One hundred seventy-seven adult patients with suspected or known brain tumours were randomised to one of two study arms to undergo two identical exams at 1.5T, one with gadobenate at 0.1 (Arm 1; 70 patients) or 0.05 (Arm 2; 107 patients) mmol/kg bodyweight, and the other with gadoterate at 0.1 mmol/kg bodyweight. The agents were injected in randomised order separated by 2–14 days. Imaging sequences (T1SE and T1GRE) and acquisition timing were identical for the two exams. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, global preference) and quantitatively for % lesion enhancement and lesion-to-background ratio (LBR). Safety assessments were performed.


In Arm 1, readers 1, 2 and 3 demonstrated highly significant global preference for gadobenate (31 vs. 1, 51 vs. 2, 43 vs. 2 patients, respectively; p<0.0001, all readers), all other qualitative endpoints (p≤0.0023; all readers) and for % enhancement (p≤0.0006) and LBR (p<0.0001). Significant (p=0.023) differences between 0.05 mmol/kg gadobenate and 0.1 mmol/kg gadoterate (in favour of gadobenate) were noted only by reader 2 for % enhancement. Study agent related adverse events were reported by 2/169 (1.2%) patients after gadobenate and by 5/175 (2.9%) patients after gadoterate.


Significantly superior morphologic information and contrast enhancement are demonstrated on brain MRI with 0.1 mmol/kg gadobenate compared to 0.1 mmol/kg gadoterate. No meaningful differences were recorded between 0.05 mmol/kg gadobenate and 0.1 mmol/kg gadoterate.

Authors’ Affiliations

Bracco Imaging SpA, Milan, Italy


© Vaneckova et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.